0
Articles |

Elevated Hepatocyte Growth Factor Level Correlates With Poor Outcome in Early-Stage and Late-Stage Adenocarcinoma of the Lung*

Jill M. Siegfried, PhD; James D. Luketich, MD; Laura P. Stabile, PhD; Neil Christie, MD; Stephanie R. Land, PhD
Author and Funding Information

*From the Departments of Pharmacology (Drs. Siegfried and Stabile), Surgery (Drs. Luketich and Christie), and Biostatistics (Dr. Land), University of Pittsburgh Cancer Institute, Pittsburgh, PA.

Correspondence to: Jill M. Siegfried, PhD, The Hillman Cancer Center, UPCI Research Pavilion, Suite 2.18, Pittsburgh, PA 15213-1863; e-mail: siegfriedjm@upmc.edu



Chest. 2004;125(5_suppl):116S-119S. doi:10.1378/chest.125.5_suppl.116S
Text Size: A A A
Published online

Extract

The 5-year survival rate for patients with all stages of lung cancer combined is only 15%. The survival rate is 48% for patients in whom disease is localized when detected, demonstrating that even when diagnosis occurs at an early stage of disease, relapse and death are common. Thus, identifying prognostic markers is critical for predicting patient survival in early disease and for determining proper therapeutic strategies. Hepatocyte growth factor (HGF) is a pleiotropic protein that induces cell proliferation and cell movement,12 and is a powerful angiogenic factor.3 It is primarily a paracrine factor that is produced by mesenchymal cells,4 although carcinoma cells may secrete HGF.56 The receptor for HGF, c-Met, is expressed by both epithelial and endothelial cells. The HGF/c-Met signaling pathway plays a significant role in the pathogenesis of many human cancers and is an attractive target for lung cancer therapy.7 The overexpression of HGF has been observed in either serum or tumor extracts of patients with lung cancer.89

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543